ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of Australia
ST SC Pharmaceuticals recently obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for injectable bivalirudin. This drug is used for the treatment of patients with moderate to high-risk acute coronary syndrome, applicable to those with unstable angina and non-ST elevation myocardial infarction, and can be used in combination with aspirin and P2Y12 antagonists
According to the Zhitong Finance APP, *ST Pharmaceuticals (002693.SZ) announced that the company recently received the marketing authorization for injectable bivalirudin issued by the Therapeutic Goods Administration (TGA) of Australia.
It is reported that injectable bivalirudin is used as an anticoagulant for the treatment of patients with moderate to high-risk acute coronary syndrome (ACS) (unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI) who are undergoing early invasive treatment, as well as patients undergoing percutaneous coronary intervention (PCI). Injectable bivalirudin is intended to be used in conjunction with aspirin. Additionally, it can be used in combination with P2Y12 antagonists (such as clopidogrel or ticagrelor)
